A detailed history of Douglas Lane & Associates, LLC transactions in Amgen Inc stock. As of the latest transaction made, Douglas Lane & Associates, LLC holds 14,340 shares of AMGN stock, worth $3.79 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
14,340
Previous 14,401 0.42%
Holding current value
$3.79 Million
Previous $4.5 Million 2.69%
% of portfolio
0.07%
Previous 0.07%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

SELL
$309.38 - $337.38 $18,872 - $20,580
-61 Reduced 0.42%
14,340 $4.62 Million
Q2 2024

Jul 08, 2024

SELL
$262.75 - $319.31 $90,386 - $109,842
-344 Reduced 2.33%
14,401 $4.5 Million
Q1 2024

Apr 11, 2024

SELL
$268.87 - $324.56 $13,443 - $16,228
-50 Reduced 0.34%
14,745 $4.19 Million
Q4 2023

Jan 17, 2024

SELL
$255.7 - $288.46 $122,736 - $138,460
-480 Reduced 3.14%
14,795 $4.26 Million
Q3 2023

Oct 16, 2023

BUY
$218.65 - $271.46 $83,961 - $104,240
384 Added 2.58%
15,275 $4.11 Million
Q2 2023

Jul 19, 2023

SELL
$214.27 - $253.37 $19,498 - $23,056
-91 Reduced 0.61%
14,891 $3.31 Million
Q1 2023

Apr 17, 2023

SELL
$225.79 - $275.2 $64,801 - $78,982
-287 Reduced 1.88%
14,982 $3.62 Million
Q4 2022

Feb 14, 2023

SELL
$229.03 - $291.01 $18,780 - $23,862
-82 Reduced 0.53%
15,269 $4.01 Million
Q4 2022

Jan 17, 2023

SELL
$229.03 - $291.01 $233,152 - $296,248
-1,018 Reduced 6.22%
15,351 $4.03 Million
Q3 2022

Oct 14, 2022

SELL
$224.46 - $253.15 $81,254 - $91,640
-362 Reduced 2.16%
16,369 $3.69 Million
Q2 2022

Jul 18, 2022

SELL
$230.71 - $256.74 $523,019 - $582,029
-2,267 Reduced 11.93%
16,731 $4.07 Million
Q1 2022

Apr 25, 2022

SELL
$219.27 - $242.57 $740,255 - $818,916
-3,376 Reduced 15.09%
18,998 $4.59 Million
Q4 2021

Jan 25, 2022

SELL
$198.88 - $227.6 $193,908 - $221,910
-975 Reduced 4.18%
22,374 $5.03 Million
Q3 2021

Oct 21, 2021

SELL
$212.27 - $248.7 $706,859 - $828,171
-3,330 Reduced 12.48%
23,349 $4.97 Million
Q2 2021

Jul 19, 2021

SELL
$233.58 - $259.14 $1.2 Million - $1.33 Million
-5,130 Reduced 16.13%
26,679 $6.5 Million
Q1 2021

Apr 19, 2021

SELL
$221.91 - $258.6 $898,735 - $1.05 Million
-4,050 Reduced 11.29%
31,809 $7.91 Million
Q4 2020

Jan 14, 2021

SELL
$216.38 - $257.67 $817,916 - $973,992
-3,780 Reduced 9.54%
35,859 $8.25 Million
Q3 2020

Oct 19, 2020

SELL
$234.65 - $260.95 $1.08 Million - $1.21 Million
-4,618 Reduced 10.43%
39,639 $10.1 Million
Q2 2020

Jul 28, 2020

SELL
$197.81 - $242.74 $626,068 - $768,272
-3,165 Reduced 6.67%
44,257 $10.4 Million
Q1 2020

Apr 20, 2020

SELL
$182.24 - $241.7 $364,844 - $483,883
-2,002 Reduced 4.05%
47,422 $9.61 Million
Q4 2019

Jan 27, 2020

SELL
$189.21 - $243.2 $438,588 - $563,737
-2,318 Reduced 4.48%
49,424 $11.9 Million
Q3 2019

Oct 16, 2019

SELL
$174.11 - $208.62 $1.81 Million - $2.17 Million
-10,389 Reduced 16.72%
51,742 $10 Million
Q2 2019

Jul 08, 2019

SELL
$166.7 - $195.41 $2.39 Million - $2.8 Million
-14,319 Reduced 18.73%
62,131 $11.4 Million
Q1 2019

Apr 23, 2019

SELL
$180.87 - $203.88 $1.39 Million - $1.57 Million
-7,695 Reduced 9.14%
76,450 $14.5 Million
Q4 2018

Jan 17, 2019

SELL
$178.4 - $208.25 $1.07 Million - $1.25 Million
-6,020 Reduced 6.68%
84,145 $16.4 Million
Q3 2018

Oct 09, 2018

SELL
$185.29 - $208.89 $827,505 - $932,902
-4,466 Reduced 4.72%
90,165 $18.7 Million
Q2 2018

Jul 23, 2018

SELL
$166.05 - $186.51 $3.6 Million - $4.05 Million
-21,699 Reduced 18.65%
94,631 $17.5 Million
Q1 2018

Apr 23, 2018

SELL
$169.43 - $198.0 $3.51 Million - $4.1 Million
-20,699 Reduced 15.11%
116,330 $19.8 Million
Q4 2017

Jan 24, 2018

SELL
$168.79 - $188.59 $3.64 Million - $4.07 Million
-21,578 Reduced 13.6%
137,029 $23.8 Million
Q3 2017

Oct 19, 2017

BUY
$167.29 - $191.0 $26.5 Million - $30.3 Million
158,607
158,607 $29.6 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Douglas Lane & Associates, LLC Portfolio

Follow Douglas Lane & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Douglas Lane & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Douglas Lane & Associates, LLC with notifications on news.